Boston Scientific Wins FTC Clearance For £3.3B BTG Deal
Law360 (August 7, 2019, 6:44 PM EDT) -- The Federal Trade Commission cleared Boston Scientific Corp.’s planned £3.3 billion ($4.2 billion) purchase of U.K.-based BTG PLC Wednesday after the company agreed to sell a cancer-treatment product line and other assets to Varian Medical Systems.
The FTC said the sale of Boston Scientific’s drug-eluting bead business and a complementary product line will help restore competition eliminated by the BTG purchase. Boston Scientific and BTG are currently the U.S.'s two largest suppliers of the microscopic polymer beads, which are used to treat liver cancers and other conditions by blocking the blood supply to tumors while delivering a chemotherapy agent.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!